These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 23493434)

  • 1. Long-term outcomes following low-dose radioiodide ablation for differentiated thyroid cancer.
    Welsh L; Powell C; Pratt B; Harrington K; Nutting C; Harmer C; Newbold K
    J Clin Endocrinol Metab; 2013 May; 98(5):1819-25. PubMed ID: 23493434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
    Scheffel RS; Zanella AB; Dora JM; Maia AL
    Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of low-dose and high-dose postoperative radioiodine therapy on the clinical outcome in patients with small differentiated thyroid cancer having microscopic extrathyroidal extension.
    Han JM; Kim WG; Kim TY; Jeon MJ; Ryu JS; Song DE; Hong SJ; Shong YK; Kim WB
    Thyroid; 2014 May; 24(5):820-5. PubMed ID: 24328997
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
    Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
    Saengsuda Y
    J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
    Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
    Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
    Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
    Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. No adverse affect in clinical outcome using low preablation diagnostic (131)i activity in differentiated thyroid cancer: refuting thyroid-stunning effect.
    Yap BK; Murby B
    J Clin Endocrinol Metab; 2014 Jul; 99(7):2433-40. PubMed ID: 24762114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.
    Schvartz C; Bonnetain F; Dabakuyo S; Gauthier M; Cueff A; Fieffé S; Pochart JM; Cochet I; Crevisy E; Dalac A; Papathanassiou D; Toubeau M
    J Clin Endocrinol Metab; 2012 May; 97(5):1526-35. PubMed ID: 22344193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients.
    Castagna MG; Cevenini G; Theodoropoulou A; Maino F; Memmo S; Claudia C; Belardini V; Brianzoni E; Pacini F
    Eur J Endocrinol; 2013 Jul; 169(1):23-9. PubMed ID: 23594687
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid.
    Besic N; Vidergar-Kralj B; Frkovic-Grazio S; Movrin-Stanovnik T; Auersperg M
    Thyroid; 2003 Jun; 13(6):577-84. PubMed ID: 12930602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary gland function 5 years after radioactive iodine ablation in patients with differentiated thyroid cancer: direct comparison of pre- and postablation scintigraphies and their relation to xerostomia symptoms.
    Jeong SY; Kim HW; Lee SW; Ahn BC; Lee J
    Thyroid; 2013 May; 23(5):609-16. PubMed ID: 23153322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of radioactive iodine for treatment of low-risk thyroid cancer: a systematic analysis of the peer-reviewed literature from 1966 to April 2008.
    Sacks W; Fung CH; Chang JT; Waxman A; Braunstein GD
    Thyroid; 2010 Nov; 20(11):1235-45. PubMed ID: 21062195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin.
    Zhang Y; Liang J; Yang X; Yang K; Lin Y
    Nucl Med Commun; 2015 Jun; 36(6):553-9. PubMed ID: 25793928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years.
    Brierley J; Tsang R; Panzarella T; Bana N
    Clin Endocrinol (Oxf); 2005 Oct; 63(4):418-27. PubMed ID: 16181234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma.
    Tsang RW; Brierley JD; Simpson WJ; Panzarella T; Gospodarowicz MK; Sutcliffe SB
    Cancer; 1998 Jan; 82(2):375-88. PubMed ID: 9445196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients.
    Chianelli M; Todino V; Graziano FM; Panunzi C; Pace D; Guglielmi R; Signore A; Papini E
    Eur J Endocrinol; 2009 Mar; 160(3):431-6. PubMed ID: 19074463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mild decreases in white blood cell and platelet counts are present one year after radioactive iodine remnant ablation.
    Molinaro E; Leboeuf R; Shue B; Martorella AJ; Fleisher M; Larson S; Tuttle RM
    Thyroid; 2009 Oct; 19(10):1035-41. PubMed ID: 19772430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.